Magaldrate

Pharmaceutical drug From Wikipedia, the free encyclopedia

Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.

Pregnancy
category
  • C
Quick facts Clinical data, Trade names ...
Magaldrate
Clinical data
Trade namesMagalat
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682683
Pregnancy
category
  • C
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNegligible
MetabolismNil
ExcretionFecal and renal
Identifiers
  • Magnesium aluminate monohydrate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.115.465 Edit this at Wikidata
Chemical and physical data
FormulaAlMg2(OH)7·H2O
Molar mass212.66 g/mol
  • InChI=1S/Al.Mg.2H2O/h;;2*1H2/p-1 checkY
  • Key:SXSTVPXRZQQBKQ-UHFFFAOYSA-M checkY
  (verify)
Close

Development

Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany).[1] In 1983, the active substance was registered as the original drug Riopan.[2]

Available forms

Magaldrate is available in the form of oral suspension or tablets.

Pharmacology

Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[3]

Interactions and adverse reactions

Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.

References

Related Articles

Wikiwand AI